Facility Evaluation And Inspection 26 28 Generic Drugs Forum 2017

Summary

Kathleen Uhl, MD, Director, Office of Jonathan Resnick, CDER, covers eCTD deadlines, the differences between 1st, 2nd, and 3rd acknowledgement notices, and ... Stephanie H. Choi, CDER Office of This premier event brings together FDA subject matter experts from every aspect of the pre-ANDA and ANDA Amy Bertha, CDER Office of Executive Programs, covers Guoping Sun, CDER Office of Pharmaceutical Quality, shares a reviewer's perspective in the Michael Kopcha, PhD, RPh, Director, Office of Elaine Lippmann, CDER Office of Regulatory Policy, discusses the statutory requirements, the process of developing a single, ... Donal Parks, CDER, provides an overview of the user fee structure under GDUFA II. He focuses on how the user fee structure ... Nallaperumal Chidambaram, CDER Office of Edward “Ted” Sherwood, CDER Office of